|
1
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Köhne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
3
|
Fuchs CS, Marshall J, Mitchell E, et al:
Randomized, controlled trial of irinotecan plus infusional, bolus,
or oral fluoropyrimidines in first-line treatment of metastatic
colorectal cancer: results from the BICC-C Study. J Clin Oncol.
25:4779–4786. 2007. View Article : Google Scholar
|
|
4
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Amado RG, Wolf M, Peeters M, et al:
Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cappuzzo F, Finocchiaro G, Rossi E, et al:
EGFR FISH assay predicts for response to cetuximab in chemotherapy
refractory colorectal cancer patients. Ann Oncol. 19:717–723. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lièvre A, Bachet JB, Boige V, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008.
|
|
8
|
Di Fiore F, Blanchard F, Charbonnier F, et
al: Clinical relevance of KRAS mutation detection in metastatic
colorectal cancer treated by Cetuximab plus chemotherapy. Br J
Cancer. 96:1166–1169. 2007.PubMed/NCBI
|
|
9
|
Khambata-Ford S, Garrett CR, Meropol NJ,
et al: Expression of epiregulin and amphiregulin and K-ras mutation
status predict disease control in metastatic colorectal cancer
patients treated with cetuximab. J Clin Oncol. 25:3230–3237. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006.PubMed/NCBI
|
|
11
|
De Roock W, Jonker DJ, Di Nicolantonio F,
et al: Association of KRAS p. G13D mutation with outcome in
patients with chemotherapy-refractory metastatic colorectal cancer
treated with cetuximab. JAMA. 304:1812–1820. 2010.PubMed/NCBI
|
|
12
|
Tejpar S, Bokemeyer C, Celik I,
Schlichting M, Sartorius U and Van Cutsem E: Influence of KRAS G13D
mutations on outcome in patients with metastatic colorectal cancer
(mCRC) treated with first-line chemotherapy with or without
cetuximab. J Clin Oncol. 29:35112010.
|
|
13
|
Peeters M, Douillard JY, Cutsem E, et al:
Evaluation of individual codon 12 and 13 mutant (MT) KRAS alleles
as prognostic and predictive biomarkers of response to panitumumab
(pmab) in patients with metastatic colorectal cancer (mCRC). Eur J
Cancer. 47(Suppl 2): 162011. View Article : Google Scholar
|
|
14
|
Dix BR, Robbins P, Soong R, et al: The
common molecular genetic alterations in Dukes' B and C colorectal
carcinomas are not short-term prognostic indicators of survival.
Int J Cancer. 59:747–751. 1994.
|
|
15
|
Iniesta P, Caldés T, Vega FJ, et al:
Prevalence of p53 overexpression or mutations, but not K-ras
mutations, in recurrent patients affected by colorectal carcinoma.
Int J Oncol. 7:319–325. 1995.PubMed/NCBI
|
|
16
|
Andersen SN, Lovig T, Breivik J, et al:
K-ras mutations and prognosis in large-bowel carcinomas. Scand J
Gastroenterol. 32:62–69. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tortola S, Marcuello E, Gonzalez I, et al:
p53 and K-ras gene mutations correlate with tumor aggressiveness
but are not of routine prognostic value in colorectal cancer. J
Clin Oncol. 17:1375–1381. 1999.PubMed/NCBI
|
|
18
|
Hirvikoski P, Auvinen A, Servomaa K, et
al: K-ras and p53 mutations and overexpressions as prognostic
factors in female rectal carcinoma. Anticancer Res. 19:685–691.
1999.PubMed/NCBI
|
|
19
|
Esteller M, Gonzalez S, Risques RA, et al:
K-ras and p16 aberrations confer poor prognosis in human colorectal
cancer. J Clin Oncol. 19:286–288. 2001.PubMed/NCBI
|
|
20
|
Laurent-Puig P, Olschwang S, Delattre O,
et al: Survival and acquired genetic alterations in colorectal
cancer. Gastroenterology. 102:1136–1141. 1992.PubMed/NCBI
|
|
21
|
Bell SM, Scott N, Cross D, et al:
Prognostic value of p53 overexpression and c-Ki-ras gene mutations
in colorectal cancer. Gastroenterology. 104:57–64. 1993.PubMed/NCBI
|
|
22
|
Lee JC, Wang ST, Lai MD, et al: K-ras gene
mutation is a useful predictor of the survival of early stage
colorectal cancers. Anticancer Res. 16:3839–844. 1996.PubMed/NCBI
|
|
23
|
Ahnen DJ, Feigl P, Quan G, et al: Ki-ras
mutation and p53 overexpression predict the clinical behavior of
colorectal cancer: a Southwest Oncology Group study. Cancer Res.
58:1149–1158. 1998.PubMed/NCBI
|
|
24
|
Bouzourene H, Gervaz P, Cerottini JP, et
al: p53 and Ki-ras as prognostic factors for Dukes' stage B
colorectal cancer. Eur J Cancer. 36:1008–1015. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andreyev HJ, Norman AR, Cunningham D, et
al: Kirsten ras mutations in patients with colorectal cancer: the
‘RASCAL II’ study. Br J Cancer. 85:692–696. 2001.
|
|
26
|
Benhattar J, Losi L, Chaubert P, et al:
Prognostic significance of K-ras mutations in colorectal carcinoma.
Gastroenterology. 104:1044–1048. 1993.PubMed/NCBI
|
|
27
|
Cerottini JP, Caplin S, Saraga E, et al:
The type of K-ras mutation determines prognosis in colorectal
cancer. Am J Surg. 175:198–202. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Span M, Moerkerk PTM, De Goeij AFPM and
Arends JW: A detailed analysis of K-ras point mutations in relation
to tumor progression and survival in colorectal cancer patients.
Int J Cancer. 69:241–245. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pajkos G, Kiss I, Sandor J, et al: The
prognostic value of the presence of mutations at the codons 12, 13,
61 of K-ras oncogene in colorectal cancer. Anticancer Res.
20:1695–1701. 2000.PubMed/NCBI
|
|
30
|
Samowitz WS, Curtin K, Schaffer D, et al:
Relationship of Ki-ras mutations in colon cancers to tumor
location, stage, and survival: a population-based study. Cancer
Epidemiol Biomarkers Prev. 9:1193–1197. 2000.PubMed/NCBI
|
|
31
|
Al-Mulla F, Going JJ, Sowden ET, et al:
Heterogeneity of mutant versus wild-type in primary and metastatic
colorectal carcinomas, and association of codon 12 valine with
early mortality. J Pathol. 185:130–138. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Uetake H, Watanabe T, Yoshino T, et al:
Clinicopathological features of patients with colorectal cancer
among KRAS wild type p. G13D and other mutations: results from a
multicenter, cross-sectional study by the Japan Study Group of KRAS
Mutation in Colorectal Cancer. J Clin Oncol. 29:36052011.
|
|
33
|
Yokota T, Ura T, Shibata N, et al: BRAF
mutation is a powerful prognostic factor in advanced and recurrent
colorectal cancer. Br J Cancer. 104:856–862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schubbert S, Shannon K and Bollag G:
Hyperactive Ras in developmental disorders and cancer. Nat Rev
Cancer. 7:295–308. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Harari PM: Epidermal growth factor
receptor inhibition strategies in oncology. Endocr Relat Cancer.
11:689–708. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kiaris H and Spandidos DA: Mutations of
ras genes in human tumours (Review). Int J Oncol. 7:413–421.
1995.
|
|
37
|
Andreyev HJ, Norman AR, Cunningham D,
Oates JR and Clarke PA: Kirsten ras mutations in patients with
colorectal cancer: the multicenter ‘RASCAL’ study. J Natl Cancer
Inst. 90:675–684. 1998.
|
|
38
|
Guerrero S, Casanova I, Farré L, Mazo A,
Capellà G and Mangues R: K-ras codon 12 mutation induces higher
level of resistance to apoptosis and predisposition to
anchorage-independent growth than codon 13 mutation or
proto-oncogene overexpression. Cancer Res. 60:6750–6756. 2000.
|
